News and Events

News and Events

KAHR Announces $46.5 Million Financing to Advance its Multifunctional Immunotherapeutic Pipeline

More

KAHR Receives Investment from Cancer Focus Fund to Support Phase 1/2 Study of KAHR’s Lead Anti-CD47 Candidate in Blood Cancers

More

KAHR Announces Exclusive Licensing Agreement with Thomas Jefferson University for Novel Platform of Bi- and Tri-Specific Fusion Proteins for Cancer Immunotherapy

More

KAHR Announces First Patient Dosed in Phase 1/2 Clinical Trial of DSP107, Bi-Functional CD47x41BB Candidate for the Treatment of Solid Tumors

More

KAHR Announces Addition of Prof. Hagop M. Kantarjian to Its Clinical Advisory Board

More

KAHR Announces Oral Presentation at the 62nd American Society of Hematology (ASH) Annual Meeting

More

KAHR Announces Two Key Appointments to Strengthen Leadership Team

More

KAHR Medical Announces FDA Clearance of IND Application for DSP107, anti-CD47 Candidate for the Treatment of Solid Tumors

More

KAHR Medical Raises $18 Million in Private Funding Round

More

KAHR Medical Announces Clinical Trial Collaboration to Evaluate DSP107 in Combination With a PD-L1 Checkpoint Inhibitor in Advanced Lung Cancer Patients

More

Contact Us

KAHR 1 Kiryat Hadassah JBP Bldg. POB 9779, Jerusalem, 9109701, Israel T. +972.73.7969196 info@kahr-medical.com